PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth signals a shrinking top line, alarming for Benjamin Graham. Confirm if it’s cyclical or structural before proceeding.
-12.41%
Negative gross profit growth suggests either falling sales or rising direct costs. Benjamin Graham would consider this a fundamental warning sign.
-27.47%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-27.47%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-27.92%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-20.00%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-20.00%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
6.47%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
6.47%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-21.77%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
92.60%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
85.56%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-3055.33%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
92.82%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
82.14%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1796.75%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-58.41%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
18.52%
3Y equity/share CAGR above 12% – Excellent recent net worth expansion. Warren Buffett would check consistent earnings retention or beneficial buybacks driving this growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Asset growth 0-5% – Minimal. Howard Marks notes the firm may be optimizing existing assets or being cautious with expansions.
-6.32%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
-20.42%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
29.66%
R&D growth 20-30% – High. Howard Marks questions ROI unless the pipeline is robust or near commercialization.
16.61%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.